|Awarded On||November 19, 2015|
|Title||Regulation of tumor aggressiveness and immune suppression in lung adenocarcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Qingyun Liu|
|Cancer Sites||Lung and Bronchus|
Lung cancer remains the leading cause of cancer related death in the world. Recent progress in the development of targeted therapeutics against mechanisms that drive the formation and growth of a subset of lung adenocarcinoma has provided breakthrough treatment to those patients. However, the vast majority of lung cancer cases still don’t have targeted therapies available. Recently, we found a novel ligand-receptor system that potentially plays a driving role in the aggressiveness of a subset of lung adenocarcinomas. This system, comprising the R-spondin (RSPO) group of secreted proteins as ligands and LGR4 as the receptor, is genetically altered to cause tumor formation in a small fract...